Mabwell Advances SST001 PET Tracer to Phase I Trial
SHANGHAI, CHINA, April 14, 2026 Mabwell (688062.SH) has announced that SST001 (18F-FD4), an innovative α-synuclein-targeted PET tracer developed by...
NMPA Approval
Advertisement
DualityBio Advances HER2 ADC Toward China Approval
SHANGHAI, China, April 9, 2026 DualityBio has announced that the China National Medical Products Administration (NMPA) has accepted the...
GSK Secures China Approval for Exdensur in Nasal Polyps Treatment
LONDON, UK, April 8, 2026 GSK has announced that China’s National Medical Products Administration (NMPA) has approved Exdensur (depemokimab),...
GSK Wins China Approval for Exdensur in Severe Asthma
LONDON, UK — March 30, 2026 In a major advancement in respiratory medicine and biologic drug innovation, GSK plc...
XellSmart Secures Dual FDA, NMPA IND for MSA-P
SUZHOU, China, March 2, 2026 XellSmart Pharmaceutical Co., Ltd. announced that it has received its fourth consecutive Investigational New...
Advertisements
Innovent Secures NMPA Approval for TABOSUN in Colon Cancer
SAN FRANCISCO, U.S. & SUZHOU, China | December 25, 2025 — Innovent Biologics announced that TABOSUN® (ipilimumab N01 injection),...
InnoCare Gains NMPA Nod for Phase II TYK2 Lupus Trial
BEIJING, China — December 23, 2025 — InnoCare Pharma has announced a major clinical development milestone with the approval...
NMPA Approves MYQORZO in China for Obstructive HCM
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 — Cytokinetics, Incorporated (NASDAQ: CYTK) announced that MYQORZO® (aficamten) has received approval...
Zhimeng Biopharma Wins Approval to Launch Phase 2 Epilepsy Trial
Shanghai, China – September 11, 2025 – Shanghai Zhimeng Biopharma, Inc. today announced that its investigational therapy CB03-154, a...
GeneseeqPrime Gains FDA 510(k) Clearance for Tumor Profiling Kit
TORONTO, Sept. 2, 2025 – Geneseeq Technology Inc. announced that its GeneseeqPrime® NGS Tumor Profiling Assay has received 510(k)...
Advertisement
